Phathom Pharmaceuticals, Inc.

NASDAQ•PHAT

CEO: Ms. Terrie J. Curran

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2019-10-25

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Contact Information

100 Campus Drive, Suite 102, Florham Park, NJ, 07932, United States

877-742-8466

www.phathompharma.com

Market Cap

$792.71M

P/E (TTM)

-3.3

17.4

Dividend Yield

52W High

$18.31

52W Low

$2.21

52W Range

49%

Rank65Top 96.0%

1.6

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 1.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$57.58M+0.00%

4-Quarter Trend

EPS

-$0.29+0.00%

4-Quarter Trend

FCF

-$4.89M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Product Revenue Growth Product revenue reached $175.1M USD in 2025, reflecting a substantial 217.1% increase over 2024 sales.

Net Loss Significantly Narrowed Net loss decreased to $221.2M USD in 2025, showing $113.1M improvement versus prior year operating results.

Commercial Adoption Metrics Over 1.1 million VOQUEZNA prescriptions filled since launch; commercial coverage now exceeds 80% of US lives.

Long-Term Exclusivity Secured NCE exclusivity for all three VOQUEZNA products is secured, extending protection through May 3, 2032.

Risk Factors

High Cash Burn Rate Operating cash usage totaled $166.8M USD in 2025; future capital needs remain uncertain despite recent financing.

Reliance on Single Product Entire revenue stream currently depends entirely on successful US commercialization of VOQUEZNA products for GERD and H. pylori.

Third-Party Manufacturing Dependence Reliance on Evonik, Catalent, and Sandoz for supply increases risk of disruption to commercial and clinical product availability.

Intellectual Property Uncertainty Patent scope and enforceability are uncertain; potential challenges could limit competitive advantage from licensed technology.

Outlook

Targeting Operating Profitability Expect operating profitability beginning in the third quarter of 2026, excluding non-cash stock-based compensation expenses.

Pipeline Expansion Underway Initiated Phase 2 clinical trial evaluating vonoprazan for Eosinophilic Esophagitis (EoE) treatment in Q4 2025.

Geographic Market Evaluation Actively evaluating potential for vonoprazan expansion into European and Canadian markets for future growth opportunities.

Cost Reduction Measures Implemented organizational restructuring in May 2025 to reduce cash burn and focus resources on core commercial execution.

Peer Comparison

Revenue (TTM)

IOVA

$263.50M

+60.6%

ANAB

$234.60M

+157.0%

MRVI

$185.74M

-28.3%

Gross Margin (Latest Quarter)

VIR

672.1%

-54902.1pp

IOVA

215.9%

+65.9pp

ANAB

199.8%

+99.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ANAB	$1.81B	-132.4	1813.8%	79.8%
OCS	$1.40B	-11.0	-62.5%	1.0%
VIR	$1.37B	-2.7	-49.3%	18.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

26.4%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 29, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data